News

HCA Healthcare Reports Third Quarter 2026 Results

Fintel·10:42HCA▼−3.4%

HCA Healthcare (NYSE:HCA) Q3 Earnings Clear EPS Bar as Payer Mix Drag Persists

HCA Q3 2026 revenue hit $19.849B, adjusted EPS of $7.22 beat estimates, but a $400M uninsured payer-mix hit tempered guidance optimism.

ChartMill·08:32HCA▼−3.4%

HCA Healthcare Stock Nears Buy Point Despite Uninsured Cost Jump

The jump in uninsured patient costs sliced $400 million from pre-tax earnings.

Yahoo·08:29HCA▼−3.4%

HCA Healthcare’s (NYSE:HCA) Q3 2026: beats on revenue, stock soars

Hospital operator HCA Healthcare (NYSE:HCA) reported Q3 2026 results beating Wall Street’s revenue expectations, with revenue up 3.6% year on year to $19.85 billion. The company expects the full year’s revenue to be around $78.25 billion, close to analysts’ consensus estimates. Its GAAP profit of $7.27 per share was 7% above analysts’ consensus estimates.

Yahoo·07:19HCA▼−3.4%

HCA Healthcare (HCA) Q3 Earnings and Revenues Top Estimates

HCA (HCA) delivered earnings and revenue surprises of +7.12% and +2.50%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Yahoo·07:15HCA▼−3.4%

What Is Drawing Fresh Attention To HCA Healthcare (HCA)?

HCA Healthcare (HCA) is back in focus ahead of Tuesday’s earnings release, with Wall Street bracing for revenue that is expected to be flat year on year after last year’s 9.6% rise. At a share price of $465.26, HCA Healthcare has logged an 11.26% 90 day share price return, while the 3 year total shareholder return of 113.14% and 5 year total shareholder return of 93.30% point to momentum that has been building over time. Spot opportunities across hospital operators by scanning our curated...

Yahoo·05:08HCA▼−3.4%

HCA Healthcare (HCA) Stock Fair Value Edges Higher After Mixed Analyst Target Changes

The latest update for HCA Healthcare points to a modestly higher fair value estimate, moving from about US$452.29 to about US$461.81, which works out to roughly a 2.1% change in the modeled price target. Street research links this shift to a blend of optimism around HCA Healthcare's long term project pipeline and cost execution, alongside caution on guidance resets, payor mix and procedure trends that keeps targets spread across a wide band. As you read on, you will see how to track this...

Yahoo

HCA Healthcare earnings: what to look for from HCA

Hospital operator HCA Healthcare (NYSE:HCA) will be reporting results this Tuesday before market hours. Here’s what investors should know.

Yahoo·04:46HCA▼−3.4%

HCA Healthcare Reports Soon: How Has The Stock Reacted To Past Earnings?

HCA Healthcare (NYSE:HCA) is scheduled to report its earnings on Tuesday, October 27, 2026. The company has a market value of about $103.4 billion. Over the last twelve months it generated $78.0 billion in revenue and $12.1 billion in operating profit, with net income of $6.8 billion.

Yahoo·01:31HCA▼−3.4%

Countdown to HCA (HCA) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS

Evaluate the expected performance of HCA (HCA) for the quarter ended September 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Yahoo·08:15HCA▼−3.4%

Will HCA Healthcare's Q3 Earnings Benefit From Higher Admissions?

HCA's Q3 results could benefit from higher admissions, occupancy and inpatient revenues, but rising costs and fewer outpatient surgeries cloud the outlook.

Yahoo·07:40HCA▼−3.4%

HCA Healthcare to Host Eighth Annual "Crush the Crisis" National Prescription Drug Take Back Day

NASHVILLE, Tenn., October 21, 2026--HCA Healthcare, Inc. (NYSE:HCA), one of the nation’s leading healthcare providers, today announced it will host its eighth annual "Crush the Crisis" national prescription drug take back day. On Saturday, Oct. 24, 2026, HCA Healthcare facilities from across the country will partner with local law enforcement to help patients, families and communities safely and anonymously dispose of unused or expired medications at more than 130 collection sites, helping keep

Yahoo·08:30HCA▼−3.4%

Analysts Estimate HCA Healthcare (HCA) to Report a Decline in Earnings: What to Look Out for

HCA (HCA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo·09:00HCA▼−3.4%

Here's How Much a $1000 Investment in HCA Healthcare Made 10 Years Ago Would Be Worth Today

Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.

Yahoo·07:30HCA▼−3.4%

Q2 Earnings Highlights: HCA Healthcare (NYSE:HCA) Vs The Rest Of The Hospital Chains Stocks

As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the hospital chains industry, including HCA Healthcare (NYSE:HCA) and its peers.

Yahoo·14:11HCA▼−3.4%

Is HCA (HCA) Using Outpatient Partnerships To Quietly Redefine Its Competitive Moat In Charleston?

On 29 September 2026, Solis Mammography and HCA Healthcare’s Trident Hospital formed a joint venture to expand breast imaging services across the Charleston market, rebranding Trident’s existing program as Solis Mammography and planning further rollouts into additional HCA Healthcare facilities in the region. This move introduces Solis Mammography’s comprehensive breast health model into South Carolina, its 26th major market, potentially deepening HCA Healthcare’s outpatient footprint in the...

Yahoo·15:21HCA▼−3.4%

HCA Healthcare (HCA) Stock Could Trade At A Discount Following Its 96% Run

HCA Healthcare has delivered strong multi year gains for shareholders, and the question now is whether the current share price is still supported by the cash the business can generate. With fresh headlines ranging from a tracking cookies lawsuit to asset sales and a payer dispute, investors are looking past the noise to what the company’s cash flows say about valuation. HCA Healthcare has returned about 96.0% over the past 3 years, which puts real weight on whether that performance lines up...

Yahoo

HCA Healthcare Is Too Healthy To Downgrade

HCA Healthcare is a Buy supported by strong revenue growth and favorable demographic trends in healthcare demand. Read more on HCA stock here.

SeekingAlpha·08:45HCA▼−3.4%

TD Cowen Maintains Buy on HCA Healthcare, Raises Price Target to $460

TD Cowen analyst Ryan Langston maintains HCA Healthcare (NYSE:HCA) with a Buy and raises the price target from $431 to $460.

Benzinga·07:26HCA▼−3.4%

HCA Healthcare (HCA) Could Be 3% Undervalued As Breast Imaging Expansion Continues

Solis Mammography’s new joint venture with HCA Healthcare (HCA) Trident Hospital brings expanded breast imaging services to Charleston, as existing operations shift under the Solis banner with planned rollouts across more HCA facilities. Against this backdrop of targeted expansion in breast imaging, HCA Healthcare’s share price has gained 8.44% over the past month and 7.37% over the last 90 days. Longer term, total shareholder returns of 84.10% over three years and 91.61% over five years show...

Yahoo·18:15HCA▼−3.4%

RBC Capital Maintains Outperform on HCA Healthcare, Raises Price Target to $496

RBC Capital analyst Ben Hendrix maintains HCA Healthcare (NYSE:HCA) with a Outperform and raises the price target from $435 to $496.

Benzinga·05:52HCA3.4%

HCA Healthcare's Q3 2026 Earnings: What to Expect

HCA Healthcare will release its third-quarter earnings later this month, and analysts anticipate a single-digit profit dip.

Yahoo·06:07HCA▼−3.4%

HCA Healthcare Presents 2026 Awards of Distinction

NASHVILLE, Tenn., September 29, 2026--HCA Healthcare, Inc. (NYSE:HCA), one of the nation’s leading healthcare providers, today presented its annual HCA Healthcare Awards of Distinction at a ceremony in Nashville, Tennessee. The HCA Healthcare Awards of Distinction, which include the Frist Humanitarian Award and the Excellence in Nursing Award, are the highest honors HCA Healthcare bestows on colleagues, nurses, physicians and volunteers, recognizing individuals who exemplify the organization’s c

Yahoo·16:30HCA▼−3.4%

Can HCA Healthcare (HCA) Overcome Healthcare’s Margin Pressures?

On September 22, BMO Capital analyst Sean Dodge initiated coverage of HCA Healthcare, Inc. (NYSE:HCA) with an Outperform rating and a $495 price target. The bullish initiation centers on HCA’s targeted capital investments in high-growth geographic markets backed by strong demographic tailwinds. Coupled with compounding efficiency gains from its ongoing “resiliency” program and digital transformation, […]

Yahoo·21:07HCA▼−3.4%

Can Shorter Hospital Stays Help HCA Handle More Patient Demand?

HCA's rising admissions and shorter hospital stays could help it meet growing patient demand while using existing capacity more efficiently.

Yahoo·08:50HCA▼−3.4%

Can HCA Sustain Earnings Growth Despite a Changing Service Mix?

HCA Healthcare's healthy volume growth faces payer-mix pressure, but cost controls, network expansion and Medicaid payments may support earnings growth.

Yahoo·10:18HCA▼−3.4%

BMO Capital Initiates Coverage of HCA Healthcare at Outperform

Fintel·17:41HCA▼−3.4%

HCA Healthcare (HCA) Shares Moved, What Is Driving Attention Today?

HCA Healthcare (HCA) is back in focus after five affiliated Texas hospitals filed suit against Independence Blue Cross, alleging more than $345,000 in unpaid claims between 2022 and 2024. At a share price of US$438.12, HCA Healthcare has seen a 2.85% 1 day share price return and a 12.99% 90 day share price return. Total shareholder return of 7.73% over one year and 80.41% over three years points to momentum that has built over time, even as the year to date share price return is down 6.86%,...

Yahoo·09:17HCA▼−3.4%

This HCA Healthcare Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Analysts initiated bullish coverage on HCA, GRDN, TTC, MRVL and PLSE, setting price targets of $495, $52, $120, $270 and $70.

Benzinga·03:49HCA▼−3.4%

BMO Capital Initiates Coverage On HCA Healthcare with Outperform Rating, Announces Price Target of $495

BMO Capital analyst Sean Dodge initiates coverage on HCA Healthcare (NYSE:HCA) with a Outperform rating and announces Price Target of $495.

Benzinga·01:32HCA▼−3.4%

Can Pediatrix Sustain Growth Despite Lower Patient Volumes?

MD posts 4% year-over-year revenue growth in the second quarter of 2026 despite lower patient volumes, aided by stronger reimbursement and acquisitions.

Yahoo·11:14

Texas hospitals sue Independence Blue Cross over denied claims

Despite a $2.8B settlement over BlueCard program disputes, five HCA-affiliated hospitals say the program still traps them in red tape.

Yahoo·10:31HCA▼−3.4%

ResMed Targets 12%-14% EPS Growth as GLP-1 Patients Lift Sleep Therapy Demand

ResMed (NYSE:RMD) outlined its growth outlook, margin strategy and portfolio plans during a Morgan Stanley discussion, with executives emphasizing demand generation, patient adherence and ongoing product innovation in sleep and respiratory care. Chairman and Chief Executive Officer Mick Farrell sai

Yahoo·16:02

HCA Healthcare (HCA) Acquires a Healthcare College. Can Training Capacity Improve Staffing?

HCA Healthcare, Inc. (NYSE:HCA) announced on September 15 that it had completed its acquisition of The College of Health Care Professions. The institution serves more than 8,000 students annually through 10 Texas campuses and online programs, offering more than 20 accredited healthcare programs. For HCA Healthcare, Inc. (NYSE:HCA), the opportunity is to connect education more […]

Yahoo·16:33HCA▼−3.4%

HCA Healthcare Sees Solid Demand as Exchange Headwinds Pressure 2026 Outlook

HCA Healthcare (NYSE:HCA) CFO Mike Marks said the hospital operator is navigating a changing policy environment in 2026 while continuing to see solid underlying demand for services outside of the health insurance exchanges. Speaking at an investor conference, Marks described the expiration of enhan

Yahoo·23:02HCA▼−3.4%

10 Health Care Stocks Whale Activity In Today’s Session

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often

Benzinga·09:35

Alluvium Increases HCA Healthcare (HCA) Holdings After Its 17.5% Selloff

Alluvium Asset Management, an asset management company, released its “Conventum – Alluvium Global Fund” second-quarter 2026 investor letter. The letter can be downloaded here. The second quarter reflected a sharp shift from geopolitical uncertainty and oil market volatility to a powerful equity rally led by semiconductor companies. Despite the broader market strength, the Fund declined […]

Yahoo·08:15HCA▼−3.4%

HCA Healthcare, Inc. (HCA) Presents at 2026 Jefferies Healthcare Services and Technology Conference Transcript

HCA Healthcare, Inc. (HCA) 2026 Jefferies Healthcare Services and Technology Conference September 15, 2026 2:50 PM EDTCompany ParticipantsMike Marks - CFO...

SeekingAlpha·05:11HCA▼−3.4%

Ondine Biomedical CTO: LANTERN results 'change the entire nature of the company'

Ondine Biomedical Inc (AIM:OBI, OTC:OBIMF) President and CTO Nicolas Loebel spoke with Proactive's Stephen Gunnion about the company's photodisinfection technology, top-line results from its pivotal phase III LANTERN trial, and the commercial opportunity for Steriwave. The 5,188-patient phase III LANTERN study, conducted across 18 major US and Canadian hospitals, showed a 40.5% lower risk of 30-day surgical site infections. Loebel said the findings "change the entire nature of the company," highlighting a favourable safety profile with no device-related serious adverse events. He discussed the significance of 14 HCA Healthcare hospitals participating in the trial and the potential pathway to the US market. Steriwave remains investigational in the US and subject to FDA approval, with Ondine planning to take the full data package forward to the FDA, having already secured Fast Track and Qualified Infectious Disease Product designations. Loebel also outlined Ondine's commercial activities outside the US and the broader potential for photodisinfection in areas including intensive care, describing a recurring-revenue model combining reusable light devices with patient-specific consumables, with growth potentially coming from both new hospital adoption and increased treatments within each hospital. For more interviews and company updates, visit Proactive’s YouTube channel. Give the video a like, subscribe to the channel and enable notifications so you don’t miss future content. Read Proactive's Editorial Policy here: https://www.proactiveinvestors.co.uk/pages/editorialPolicy #OndineBiomedical #StereoWave #LANTERNTrial #Phase3Trial #SurgicalSiteInfections #InfectionPrevention #PhotoDisinfection #AntimicrobialResistance #HealthcareTechnology #MedTech #FDA #ClinicalTrials #HospitalInfections #HealthcareInnovation #Biotech #Investing #InvestorNews #ProactiveInvestors

HCA Healthcare Completes Acquisition of the College of Health Care Professions

NASHVILLE, Tenn., September 15, 2026--HCA Healthcare, Inc. (NYSE:HCA), one of the nation’s leading healthcare providers, today announced that it has completed the previously announced acquisition of The College of Health Care Professions (CHCP).

Yahoo·08:30HCA▼−3.4%

RoundTable Healthcare Partners Appoints Ed Jones as Operating Partner

RoundTable Healthcare Partners, an operating-oriented private equity firm focused exclusively on the healthcare industry, announced today that Ed Jones has joined the firm as an Operating Partner.

Yahoo·08:28

CVS Still Sees 'High-Trend' Cost Growth; Oscar, UNH Stock Fall

CVS Health noted a continuation of "high-trend" medical cost growth at a Wells Fargo investor conference on Wednesday, helping to put a spring in the step of hospital stocks including HCA Healthcare, while souring the mood of managed care investors. Shares of CVS stock came away relatively unscathed, while UnitedHealth slipped and Oscar Health stumbled. CVS management's comments about medical cost trends were brief and vague, while Wells Fargo conference presentations by HCA and Universal Health Services didn't appear to provide updates to Q3 trends since Q2 earnings calls.

Yahoo·14:05HCA▼−3.4%

HCA Healthcare, Inc. (HCA) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

SeekingAlpha·08:47HCA▼−3.4%

HCA Healthcare CEO Says Guidance For Balance Of Year Does Not Assume A Rebound In Surgery

- conference call

Benzinga·06:32HCA▼−3.4%

HCA Healthcare Delivers Consistent Message Around H2 Cadence Expectations, RBC Says

HCA Healthcare's (HCA) management delivered a consistent message around second-half cadence expectat

Yahoo·11:43HCA▼−3.4%

RBC Capital Reiterates Outperform on HCA Healthcare, Maintains $435 Price Target

RBC Capital analyst Ben Hendrix reiterates HCA Healthcare (NYSE:HCA) with a Outperform and maintains $435 price target.

Benzinga·06:54HCA▼−3.4%

The Bull Case For HCA Healthcare (HCA) Could Change Following 2026 Guidance Cut And Payer Mix Strain

HCA Healthcare recently cut its full-year 2026 earnings guidance, citing a worsening payer mix after Affordable Care Act subsidy expirations, softer high-margin elective surgeries, and rising costs that also prompted targeted corporate and support-function layoffs and at least one hospital divestiture. These actions, alongside an estimated US$400 million quarterly revenue impact from payer shifts and an ongoing legal review of prior disclosures, highlight how policy-driven reimbursement...

Yahoo·15:07HCA▼−3.4%

HCA Healthcare (HCA) Faces Securities Fraud Investigation With Shareholder Risks In Focus

Pomerantz Law Firm has launched an investigation into potential securities fraud and unlawful business practices at HCA Healthcare (NYSE:HCA). The probe focuses on whether HCA Healthcare and certain executives misled investors or breached fiduciary duties. The investigation could lead to future legal claims on behalf of shareholders depending on its findings. This kind of legal scrutiny highlights broader questions about risk, disclosure and income reliability across the healthcare sector...

HCA Healthcare (HCA) Could Be 11% Below Fair Value As Guidance Gets Cut

HCA Healthcare (HCA) shares remain under pressure after the company cut its 2026 profit guidance, citing a weaker payer mix that reduced quarterly revenue by about $400 million and triggered fresh investor scrutiny. Against that backdrop, HCA Healthcare’s recent share price moves have been choppy, with a 1 day share price return of 1.78% after the guidance cut, a 90 day share price return of 9.96%, and a year to date share price decline of 13.01% at a last close of US$409.20. The 3 year total...

Yahoo·17:11HCA▼−3.4%

Is HCA Healthcare Stock Underperforming the Nasdaq?

HCA Healthcare has underperformed the Nasdaq over the past year, but analysts are cautiously optimistic about the stock’s prospects.

Yahoo·11:52HCA▼−3.4%

Community Health Systems to Participate in the Wells Fargo 21st Annual Healthcare Conference

FRANKLIN, Tenn., September 02, 2026--Community Health Systems, Inc. (NYSE:CYH) today announced that management will participate in the Wells Fargo 21st Annual Healthcare Conference to be held September 8-10, 2026.

Yahoo·12:00

Do Wall Street Analysts Like HCA Healthcare Stock?

Despite trailing the broader market over the past year, HCA Healthcare continues to command a moderately optimistic outlook from Wall Street analysts, who see room for further upside in the stock.

Yahoo·08:33HCA▼−3.4%

HCA Healthcare, Inc. to Present at September Conferences

NASHVILLE, Tenn., August 20, 2026--HCA Healthcare, Inc. (NYSE: HCA) is scheduled to present at the following healthcare conferences:

Yahoo·17:30HCA▼−3.4%

Universal Health Shares Drop 21% YTD: Should You Buy Now?

UHS' 21% YTD slide has cheapened its valuation, but weaker volumes, ACA pressure and lower growth forecasts keep risks elevated.

Yahoo·13:43

JP Morgan Maintains Neutral on HCA Healthcare, Lowers Price Target to $425

JP Morgan analyst Benjamin Rossi maintains HCA Healthcare (NYSE:HCA) with a Neutral and lowers the price target from $490 to $425.

Benzinga·10:03HCA▼−3.4%

Outpatient & Specialty Care Stocks Q2 Teardown: U.S. Physical Therapy (NYSE:USPH) Vs The Rest

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at U.S. Physical Therapy (NYSE:USPH) and its peers.

Yahoo·15:54

Palantir Stock Climbs as Enterprise AI Demand Keeps Growing

Palantir Stock Rises as Fresh AI Demand Keeps Post-Earnings Momentum Alive

Yahoo·15:07

Could HCA Healthcare, Inc. (HCA) Stock Rebound After Guidance Cuts and Payer Pressure?

HCA Healthcare, Inc. (NYSE:HCA) reported its second-quarter 2026 financial results on July 24, confirming the figures previewed earlier in the month. While top-line growth remained healthy, a visible deterioration in payer mix and a revision to full-year profitability guidance triggered immediate target cuts across Wall Street. In its Q2 results, HCA Healthcare, Inc. reported that […]

Yahoo·18:17HCA▼−3.4%